Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives
The present invention refers to a new enzymatic process for obtaining 17α-monoesters of cortexolone and/or its 9,11-dehydroderivatives starting from the corresponding 17α,21-diesters which comprises an enzymatic alcoholysis reaction. Furthermore, the present invention refers to new crystalline forms of cortexolone-17α-propionate and 9,11-dehydro-cortexolone 17α-butanoate.
1. A composition comprising crystalline form I of cortexolone-17α-propionate characterized by an IR as shown in FIG. 3 , a DRX as shown in FIG. 1 , or a DRX with at least peaks at about: 7.6, 8.4, 14.3, 14.8, 15.7, 17.0, and 20.1 degrees 2theta, and crystalline form III of cortexolone-17α-propionate characterized by an IR as shown in FIG. 9, 12 , or 15 , a DRX as shown in FIG. 7, 10 , or 13 , or a DRX with at least peaks at about: 6.2, 12.6, 14.1, 14.3, 16.0, 22.4, and 23.7 degrees 2theta.
2. The composition of claim 1 , further comprising at least one physiologically acceptable excipient.
3. The composition of claim 2 , wherein the at least one physiologically acceptable excipient is propylene glycol, cetylic alcohol, glyceryl monostearate, liquid paraffin, or a combination of any of the foregoing.
4. The composition of claim 2 , further comprising mixed tocopherols, polysorbate 80, or a combination thereof.
5. The composition of claim 2 , wherein the composition is in the form of a tablet, capsule, powder, pellet, suspension, emulsion, cream, gel, ointment, lotion, or paste.
6. The composition of claim 2 , wherein the composition is in the form of a solid, semi-solid, or a paste.
7. The composition of claim 5 , wherein the composition is in the form of a cream.
8. The composition of claim 7 , wherein the composition further comprises solubilized cortexolone-17α-propionate.
9. The composition of claim 8 , wherein the solubilized cortexolone-17α-propionate is present in the composition in a concentration of from 0.1 to 2% by weight of the composition.
10. The composition of claim 8 , wherein the solubilized cortexolone-17α-propionate, crystalline form I of cortexolone-17α-propionate, and crystalline form III of cortexolone-17α-propionate together comprise 0.1 to 2% by weight of the composition or comprise 0.2 to 1% by weight of the composition.
11. A method of treating a pathology affecting the skin and/or the cutaneous appendages, wherein the pathology affecting the skin and/or the cutaneous appendages is acne, androgenetic alopecia, hirsutism, or seborrheic dermatitis, the method comprising topically administering to a subject in need thereof an effective amount of a composition comprising crystalline form I of cortexolone-17α-propionate characterized by an IR as shown in FIG. 3 , a DRX as shown in FIG. 1 , or a DRX with at least peaks at about: 7.6, 8.4, 14.3, 14.8, 15.7, 17.0, and 20.1 degrees 2theta, and crystalline form III of cortexolone-17α-propionate characterized by an IR as shown in FIG. 9, 12 , or 15 , a DRX as shown in FIG. 7, 10 , or 13 , or a DRX with at least peaks at about: 6.2, 12.6, 14.1, 14.3, 16.0, 22.4, and 23.7 degrees 2theta.
12. The method of claim 11 , wherein the pathology affecting the skin and/or the cutaneous appendages is acne.
13. The method of claim 11 , wherein the pathology affecting the skin and/or the cutaneous appendages is androgenetic alopecia.
14. The method of claim 11 , wherein the pathology affecting the skin and/or the cutaneous appendages is hirsutism.
15. The method of claim 11 , wherein the pathology affecting the skin and/or the cutaneous appendages is seborrheic dermatitis.